Detail

Description

Expression Detail
Experiment ID:
EXP00336
Reference:
  • Title: MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
  • Author: Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, Ochiai A
  • Journal: PloS one.2015;10(2):e0118220.doi:10.1371/journal.pone.0118220.
  • Abstract: It is difficult to detect pancreatic cancer or biliary-tract cancer at an early stage using current diagnostic technology. Utilizing microRNA (miRNA) markers that are stably present in peripheral blood, we aimed to identify pancreatic and biliary-tract cancers in patients. With "3D-Gene", a highly sensitive microarray, we examined comprehensive miRNA expression profiles in 571 serum samples obtained from healthy patients, patients with pancreatic, biliary-tract, or other digestive cancers, and patients with non-malignant abnormalities in the pancreas or biliary tract. The samples were randomly divided into training and test cohorts, and candidate miRNA markers were independently evaluated. We found 81 miRNAs for pancreatic cancer and 66 miRNAs for biliary-tract cancer that showed statistically different expression compared with healthy controls. Among those markers, 55 miRNAs were common in both the pancreatic and biliary-tract cancer samples. The previously reported miR-125a-3p was one of the common markers; however, it was also expressed in other types of digestive-tract cancers, suggesting that it is not specific to cancer types. In order to discriminate the pancreato-biliary cancers from all other clinical conditions including the healthy controls, non-malignant abnormalities, and other types of cancers, we developed a diagnostic index using expression profiles of the 10 most significant miRNAs. A combination of eight miRNAs (miR-6075, miR-4294, miR-6880-5p, miR-6799-5p, miR-125a-3p, miR-4530, miR-6836-3p, and miR-4476) achieved a sensitivity, specificity, accuracy and AUC of 80.3%, 97.6%, 91.6% and 0.953, respectively. In contrast, CA19-9 and CEA gave sensitivities of 65.6% and 40.0%, specificities of 92.9% and 88.6%, and accuracies of 82.1% and 71.8%, respectively, in the same test cohort. This diagnostic index identified 18/21 operable pancreatic cancers and 38/48 operable biliary-tract cancers in the entire cohort. Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
  • PMID: 25706130
Expression Profile:
  • Description:MicroRNA markers for the diagnosis of pancreatic and biliary tract cancers
  • Organism:Homo sapiens
  • Source:GEO
  • Source ID:GSE59856
  • Platform: GPL18941
  • Number of samples:571
  • Overall design:Prospective miRNA markers for pancreatic/biliary tract cancer were selected in the training cohort. Using these miRNAs, discriminant analysis was performed, and the diagnostic accuracy, sensitivity and specificity were calculated in the test cohort.
  • Instrument:3D-Gene Human miRNA V20_1.0.0
Design and Sample:
  • Cancer Type:colon cancer
  • Cancer SubType:N/A
  • Cell Line:N/A
  • Experimental Design:blood
  • Case Sample:blood from colon cancer
  • Control Sample:normal blood
  • Num of Case:50
  • Num of Control:150
  • Quantification Software:limma
  • Num of miRNAs:2555
Identification:
  • Num of Up:507
  • Num of Down:341
Time Info:
  • Create Time2016-03-14
  • Update Time:2021-05-27

Differentially Expressed miRNAs List

Status:
miRNA ID Cancer Type Design logFC AveExpr T value P value adj Pvalue Status Plot

Functional Chart